# Kivu Bioscience

> Kivu Bioscience is a clinical-stage biotechnology company in San Mateo, California, building next-generation antibody-drug conjugates (ADCs) for solid tumors. Founded by BioGeneration Ventures and led by ADC veteran Mohit Trikha, the company licenses Synaffix's GlycoConnect and HydraSpace site-specific conjugation technology to engineer more homogeneous, stable ADCs that aim to widen the therapeutic window - hitting tumors harder while sparing healthy tissue. Backed by a $92 million Series A led by Novo Holdings, Kivu has moved its lead candidates KIVU-107 (PTK7) and KIVU-305 (CEACAM5) into Phase 1 clinical trials.

- **Founded:** 2024
- **Headquarters:** San Mateo, California, United States
- **Founders:** BioGeneration Ventures (Founding Investor / Company Creator), Mohit Trikha (President, CEO & Chief Operating Officer)
- **Team size:** ~25 employees
- **Products:** KIVU-107, KIVU-305, KIVU-495, KIVU-202
- **Notable:** Raised a $92 million Series A led by Novo Holdings in October 2024., Advanced lead candidate KIVU-107 into a Phase 1 clinical trial, with first patient dosed in January 2026., Secured Australian HREC approval and CTN clearance to begin a first-in-human Phase 1 trial of KIVU-305 in 2026.

## Products & services

- **KIVU-107** — Next-generation PTK7-targeting antibody-drug conjugate for advanced solid tumors; first patient dosed in Phase 1 in January 2026.
- **KIVU-305** — CEACAM5-targeted ADC for solid tumors (colorectal, pancreatic, non-small cell lung cancer) using GlycoConnect conjugation, HydraSpace linker and SYNtecan E topoisomerase-inhibitor payload; entered Phase 1 in 2026.
- **KIVU-495** — Development-stage ADC program against an undisclosed target for solid tumors.
- **KIVU-202** — Development-stage ADC program against an undisclosed target for solid tumors.

## Achievements

- Raised a $92 million Series A led by Novo Holdings in October 2024.
- Advanced lead candidate KIVU-107 into a Phase 1 clinical trial, with first patient dosed in January 2026.
- Secured Australian HREC approval and CTN clearance to begin a first-in-human Phase 1 trial of KIVU-305 in 2026.
- Presented preclinical data at World ADC San Diego 2025, World ADC London 2026, and AACR Annual Meeting 2026.
- Built two clinical-stage ADC programs and additional development candidates within roughly two years of founding.

## Latest updates

- **2026-04** — Announced it would present preclinical data on its next-generation ADC programs at the AACR Annual Meeting 2026.
- **2026-02** — Presented KIVU-305 preclinical data at World ADC London 2026 and advanced the CEACAM5-targeted program into a Phase 1 clinical trial.
- **2026-01** — Dosed the first patient in the Phase 1 trial of KIVU-107, its PTK7-targeting ADC for advanced solid tumors.
- **2025-11** — Presented preclinical data for KIVU-107 demonstrating potent, durable anti-tumor activity and a wide therapeutic index at World ADC San Diego 2025.
- **2024-10** — Closed a $92 million Series A financing led by Novo Holdings.

## Links

- Website: https://kivubioscience.com
- LinkedIn: https://www.linkedin.com/company/kivubioscience

---

Profile page: https://yespress.io/kivu-bioscience
Published by YesPress — https://yespress.io
Last updated: 2026-07-11